Sign in
RPHM Stock Price, Chart, Stats & News
Reneo Pharmaceuticals, Inc.
Save
60.84M
Market cap
–
Current P/E
–
Forward P/E
RPHM chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | – |
ROE | – |
D/E | 0.01x |
Interest coverage ratio | 15737.50x |
RPHM valuation
P/E | – |
P/S | – |
P/B | 4.38x |
P/CF | -4.75x |
P/FCF | -1.17x |
P/OCF | -4.75x |
PEG | – |
EV multiple | -2.53x |
About
Reneo Pharmaceuticals, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to creating therapies for individuals suffering from uncommon inherited mitochondrial disorders. The company's lead candidate, REN001, functions as a selective peroxisome proliferator-activated receptor delta agonist. This compound is currently undergoing Phase IIb clinical trials for patients with primary mitochondrial myopathies.
Similar securities
Based on sector and market capitalization
Report issue